Satish Allur Mallanna
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Satish Allur Mallanna has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Abdullah M. Shbeer
Department of Surgery, Faculty of Medicine, Jazan University, Jazan, Saudi Arabia
1 shared publication Chaithra Maheshwari N.
Department of Microbiology, JSS Academy of Higher Education & Research, Mysuru, Karnataka, India
1 shared publication- Chandan Shivamallu
Department of Biotechnology and Bioinformatics, School of Life Sciences, JSS Academy of Higher Education and Research, Mysuru, India
1 shared publication H.L. Kalabharathi
JSS Med Coll, Dept Pharmacol, Mysuru, India
1 shared publication- Kalabharathi Hampapura Lakkappa Gowda
Department of Pharmacology, JSS Medical College, JSS Academy of Higher Education and Research, Mysuru 570015, Karnataka, India
1 shared publication - Lakshmi Ranganatha Venkataravanappa
Department of Chemistry, The National Institute of Engineering, Mysuru, India
1 shared publication
Latest Publications
- Open Access
Advancements in understanding and treating psoriasis: a comprehensive review of pathophysiology, diagnosis, and therapeutic approaches
Psoriasis is a chronic autoimmune disease affecting millions worldwide. This condition is characterized by scaly, red patches of skin that can be painful, itchy, and disfiguring. This non-contagious illness forms plaques and accelerates the dermal cell’s life cycle. This review provides a comprehensive overview of the current knowledge on psoriasis, covering its definition, prevalence, causes, pathogenesis, clinical features, diagnosis, and treatment options. The psychosocial impact of psoriasis on patients and their coping mechanisms is also explored. Biologic agents, which target specific cytokines involved in psoriasis pathogenesis, have revolutionized psoriasis treatment and have significantly improved patient outcomes. However, effective and safe treatments for moderate to severe psoriasis are still needed. Future research directions include the development of biomarkers for predicting disease severity and treatment response, investigating new therapeutic targets like the microbiome and epigenetics, and leveraging advancements in technology and genomics for deeper insights into psoriasis pathogenesis and treatment. This study summarizes the key aspects of psoriasis, including its epidemiology, pathophysiology, clinical traits, disease burden, and management. However, further research is needed to improve treatment outcomes and enhance the quality of life for patients affected by this complex condition.
Open AccessAdvancements in understanding and treating psoriasis: a comprehensive review of pathophysiology, diagnosis, and therapeutic approaches
Psoriasis is a chronic autoimmune disease affecting millions worldwide. This condition is characterized by scaly, red patches of skin that can be painful, itchy, and disfiguring. This non-contagious illness forms plaques and accelerates the dermal cell’s life cycle. This review provides a comprehensive overview of the current knowledge on psoriasis, covering its definition, prevalence, causes, pathogenesis, clinical features, diagnosis, and treatment options. The psychosocial impact of psoriasis on patients and their coping mechanisms is also explored. Biologic agents, which target specific cytokines involved in psoriasis pathogenesis, have revolutionized psoriasis treatment and have significantly improved patient outcomes. However, effective and safe treatments for moderate to severe psoriasis are still needed. Future research directions include the development of biomarkers for predicting disease severity and treatment response, investigating new therapeutic targets like the microbiome and epigenetics, and leveraging advancements in technology and genomics for deeper insights into psoriasis pathogenesis and treatment. This study summarizes the key aspects of psoriasis, including its epidemiology, pathophysiology, clinical traits, disease burden, and management. However, further research is needed to improve treatment outcomes and enhance the quality of life for patients affected by this complex condition.
- 27 January 2025
- Published by A and V Publications in Research Journal of Pharmacy and Technology
- Vol. 18 (1) , 58-62
Pharmacological Evaluation of S-Amlodipine and Nimodipine as Bronchial Smooth Muscle Relaxants in Guinea Pigs:Ex-Vivo Study
Background: S-amlodipine and Nimodipine, two members of the dihydropyridine calcium channel blocker family, were originally developed to treat cardiovascular disorders, and have shown significant potential in their ability to relax bronchial smooth muscle. Hence, we evaluated the anti-asthmatic potential of L-type calcium channel blocker properties of S-amlodipine and Nimodipine using guinea pig animal models. Materials and Methods: Twenty-four healthy adult guinea pigs were divided into four groups, each group comprised 6 guinea pigs used to study acetylcholine and histamine-induced bronchospasm models. Each group of animals received normal saline, salbutamol (10mg/kg, p.o), nimodipine (40mg/kg, p.o), and S-amlodipine (1.5mg/kg, p.o) respectively for 5 days. The anti-asthmatic effect of each guinea pig was evaluated by exposing them to 0.25% histamine aerosol and 10% acetylcholine chloride, and recording the pre-convulsive dyspnea time. Result: The S-amlodipine demonstrated superior efficacy by significantly increasing pre-convulsive dyspnea time (PCD) compared to nimodipine in both models of bronchoconstriction. S-amlodipine and Nimodipine exhibited significant bronchial smooth muscle relaxant activity compared to the control group, although they did not perform as effectively as the salbutamol drug. Conclusion: The results of our study showed that S-amlodipine and Nimodipine exhibit notable bronchial smooth muscle relaxant activity compared to the control group. However, they do not match the effectiveness of the salbutamol drug.
- 27 January 2025
- Published by A and V Publications in Research Journal of Pharmacy and Technology
- Vol. 18 (1) , 58-62
Pharmacological Evaluation of S-Amlodipine and Nimodipine as Bronchial Smooth Muscle Relaxants in Guinea Pigs:Ex-Vivo Study
Background: S-amlodipine and Nimodipine, two members of the dihydropyridine calcium channel blocker family, were originally developed to treat cardiovascular disorders, and have shown significant potential in their ability to relax bronchial smooth muscle. Hence, we evaluated the anti-asthmatic potential of L-type calcium channel blocker properties of S-amlodipine and Nimodipine using guinea pig animal models. Materials and Methods: Twenty-four healthy adult guinea pigs were divided into four groups, each group comprised 6 guinea pigs used to study acetylcholine and histamine-induced bronchospasm models. Each group of animals received normal saline, salbutamol (10mg/kg, p.o), nimodipine (40mg/kg, p.o), and S-amlodipine (1.5mg/kg, p.o) respectively for 5 days. The anti-asthmatic effect of each guinea pig was evaluated by exposing them to 0.25% histamine aerosol and 10% acetylcholine chloride, and recording the pre-convulsive dyspnea time. Result: The S-amlodipine demonstrated superior efficacy by significantly increasing pre-convulsive dyspnea time (PCD) compared to nimodipine in both models of bronchoconstriction. S-amlodipine and Nimodipine exhibited significant bronchial smooth muscle relaxant activity compared to the control group, although they did not perform as effectively as the salbutamol drug. Conclusion: The results of our study showed that S-amlodipine and Nimodipine exhibit notable bronchial smooth muscle relaxant activity compared to the control group. However, they do not match the effectiveness of the salbutamol drug.
- Open Access
- 30 August 2024
- Published by Combinatorial Press in Journal of Pioneering Medical Sciences
- Vol. 13 (5) , 74-78
A Study of Prescription Pattern of Anti-Diabetic Drugs and Usage of Teneligliptin for Type II Diabetis Mellitus
Background: Prescription pattern studies are a tool for assessing the prescribing, dispensing, and distribution of medicines. Diabetes mellitus (DM) is a spectrum of metabolic disorders as a consequence of different … Background: Prescription pattern studies are a tool for assessing the prescribing, dispensing, and distribution of medicines. Diabetes mellitus (DM) is a spectrum of metabolic disorders as a consequence of different …
- 30 August 2024
- Published by Combinatorial Press in Journal of Pioneering Medical Sciences
- Vol. 13 (5) , 74-78
Open AccessA Study of Prescription Pattern of Anti-Diabetic Drugs and Usage of Teneligliptin for Type II Diabetis Mellitus
Background: Prescription pattern studies are a tool for assessing the prescribing, dispensing, and distribution of medicines. Diabetes mellitus (DM) is a spectrum of metabolic disorders as a consequence of different … Background: Prescription pattern studies are a tool for assessing the prescribing, dispensing, and distribution of medicines. Diabetes mellitus (DM) is a spectrum of metabolic disorders as a consequence of different …
- Open Access
Discovery of Novel Coumarin Derivatives as Potential Dual Inhibitors against α-Glucosidase and α-Amylase for the Management of Post-Prandial Hyperglycemia via Molecular Modelling Approaches
Coumarin derivatives are proven for their therapeutic uses in several human diseases and disorders such as inflammation, neurodegenerative disorders, cancer, fertility, and microbial infections. Coumarin derivatives and coumarin-based scaffolds gained renewed attention for treating diabetes mellitus. The current decade witnessed the inhibiting potential of coumarin derivatives and coumarin-based scaffolds against α-glucosidase and α-amylase for the management of postprandial hyperglycemia. Hyperglycemia is a condition where an excessive amount of glucose circulates in the bloodstream. It occurs when the body lacks enough insulin or is unable to correctly utilize it. With open-source and free in silico tools, we have investigated novel 80 coumarin derivatives for their inhibitory potential against α-glucosidase and α-amylase and identified a coumarin derivative, CD-59, as a potential dual inhibitor. The ligand-based 3D pharmacophore detection and search is utilized to discover diverse coumarin-like compounds and new chemical scaffolds for the dual inhibition of α-glucosidase and α-amylase. In this regard, four novel coumarin-like compounds from the ZINC database have been discovered as the potential dual inhibitors of α-glucosidase and α-amylase (ZINC02789441 and ZINC40949448 with scaffold thiophenyl chromene carboxamide, ZINC13496808 with triazino indol thio phenylacetamide, and ZINC09781623 with chromenyl thiazole). To summarize, we propose that a coumarin derivative, CD-59, and ZINC02789441 from the ZINC database will serve as potential lead molecules with dual inhibition activity against α-glucosidase and α-amylase, thereby discovering new drugs for the effective management of postprandial hyperglycemia. From the reported scaffold, the synthesis of several novel compounds can also be performed, which can be used for drug discovery.
Open AccessDiscovery of Novel Coumarin Derivatives as Potential Dual Inhibitors against α-Glucosidase and α-Amylase for the Management of Post-Prandial Hyperglycemia via Molecular Modelling Approaches
Coumarin derivatives are proven for their therapeutic uses in several human diseases and disorders such as inflammation, neurodegenerative disorders, cancer, fertility, and microbial infections. Coumarin derivatives and coumarin-based scaffolds gained renewed attention for treating diabetes mellitus. The current decade witnessed the inhibiting potential of coumarin derivatives and coumarin-based scaffolds against α-glucosidase and α-amylase for the management of postprandial hyperglycemia. Hyperglycemia is a condition where an excessive amount of glucose circulates in the bloodstream. It occurs when the body lacks enough insulin or is unable to correctly utilize it. With open-source and free in silico tools, we have investigated novel 80 coumarin derivatives for their inhibitory potential against α-glucosidase and α-amylase and identified a coumarin derivative, CD-59, as a potential dual inhibitor. The ligand-based 3D pharmacophore detection and search is utilized to discover diverse coumarin-like compounds and new chemical scaffolds for the dual inhibition of α-glucosidase and α-amylase. In this regard, four novel coumarin-like compounds from the ZINC database have been discovered as the potential dual inhibitors of α-glucosidase and α-amylase (ZINC02789441 and ZINC40949448 with scaffold thiophenyl chromene carboxamide, ZINC13496808 with triazino indol thio phenylacetamide, and ZINC09781623 with chromenyl thiazole). To summarize, we propose that a coumarin derivative, CD-59, and ZINC02789441 from the ZINC database will serve as potential lead molecules with dual inhibition activity against α-glucosidase and α-amylase, thereby discovering new drugs for the effective management of postprandial hyperglycemia. From the reported scaffold, the synthesis of several novel compounds can also be performed, which can be used for drug discovery.